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RESUMO 
 
A artrite reumatoide (AR) é uma doença autoimune sistémica que se caracteriza pela 
inflamação crónica das pequenas articulações, particularmente das mãos, bem como 
articulações maiores, que incluem os joelhos e tornozelos. A prevalência da doença é de 
cerca de 1% na população mundial adulta e é mais frequente nas mulheres do que nos 
homens (numa proporção de 3:1). Se não for tratada, a AR origina destruição articular, com 
erosão óssea e da cartilagem.  
 
O diagnóstico da AR é feito de acordo com critérios definidos pelo American College of 
Rheumatology (ACR)/ European League Against Rheumatism (EULAR), baseados numa 
avaliação radiológica e atribuição de pontuação relativa ao número de articulações afetadas; 
serologia de autoanticorpos IgM específicos para o fragmento Fc de imunoglobulinas IgG 
(fator reumatoide, RF) ou para péptidos cíclicos citrulinados modificados pós-
traducionalmente por incorporação de citrulina por ação das peptidil arginina deaminases 
(anticorpos anti-proteínas citrulinadas, ACPA ou anti-CCP); quantificação de fatores de 
inflamação (velocidade de sedimentação eritrocitária e proteína-C reativa); e duração da 
doença.  
 
A etiologia da doença é desconhecida, mas sabe-se que a influência do genótipo e do 
ambiente parecem ser fatores essenciais para o início do processo inflamatório. Em termos 
de predisposição genética, a AR está associada a mutações no gene HLA-DRB1 que 
pertence ao complexo maior de histocompatibilidade (MHC) classe II, tendo sido identificada 
uma curta sequência de aminoácidos comum às proteínas codificadas por todos os alelos 
de risco - o shared epitope. A AR está também associada a outros genes como o PTPN22 e 
CTLA-4, entre outros. Em relação aos fatores ambientais, a maior associação descrita está 
relacionada com o tabagismo, sendo que o risco parece ser maior em indivíduos portadores 
do shared epitope. O efeito da exposição a alguns agentes infeciosos é controverso, mas 
alguns estudos indicam que poderá levar à formação de complexos imunes, implicados na 
AR. Também algumas alterações hormonais na mulher, como a gravidez, amamentação e 
contraceção oral, podem influenciar o desenvolvimento da doença.  
 
No processo inflamatório da AR ocorre uma resposta celular e humoral que contribui para o 
desenvolvimento da sinovite, ou seja, a inflamação da membrana sinovial, que é a 
membrana que reveste a articulação. A hiperplasia da sinóvia resulta de uma migração e 
excessiva infiltração de linfócitos T e B, plasmócitos, células dendríticas, macrófagos, 
neutrófilos e mastócitos, assim como da ativação dos FLS – fibroblast‐like synoviocytes – 
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que produzem citocinas pro-inflamatórias, provocando a ativação de outras células. A 
ativação de macrófagos através dos recetores Fc gama por complexos imunes que se 
formam a partir de autoanticorpos (RF e ACPA), produzidos por células B autoreactivas, 
juntamente com estímulos derivados de células T activadas, conduz à libertação de 
citocinas como a IL-1, IL-6, IL-15, INF-γ e TNF. Algumas destas citocinas ativam células 
sinoviais residentes a produzir enzimas proteolíticas, como a colagenase e 
metaloproteinases da matriz que medeiam a destruição da cartilagem. A destruição óssea 
também ocorre devido ao aumento da atividade dos osteoclastos, ativados através das 
ligações RANK/ RANK-L.  
 
Nos últimos anos, os linfócitos B têm sido alvo de investigação, particularmente após a 
eficácia clínica observada com a terapia de depleção de células B com rituximab (anticorpo 
monoclonal anti-CD20). De facto, os linfócitos B podem contribuir de diversas formas para o 
desenvolvimento da AR, tais como: 1) produção de autoanticorpos como o RF e os ACPA, 
que formam complexos imunes que se depositam nas articulações e causam inflamação; 2) 
apresentação de antigénios e ativação de linfócitos T; 3) secreção de citocinas; 4) ativação 
de osteoclastos que levam à erosão óssea; 5) imunoregulação por células B reguladoras, 
que produzem citocinas anti-inflamatórias (IL-10 e TGF-β1) que inibem células T ativadas e 
restauram o balanço TH1/TH2. 
 
Apesar da AR não ter cura, é fundamental estabelecer um diagnóstico precoce para que se 
possa proceder ao tratamento e reduzir os sintomas no doente e a progressão da doença o 
mais rapidamente possivel. O tratamento da AR faz-se com anti-inflamatórios não esteroides 
(AINES), sendo que estes apenas diminuem a atividade inflamatória;  corticoesteróides; 
DMARDs - agentes antirreumáticos modificadores da doença – sintéticos, onde se 
encontram o metotrexato (MTX), sulfassalazina (SSZ), hidroxicloroquina (HCQ) e a 
leflunomida, ou biológicos, que são geralmente anticorpos monoclonais que bloqueiam 
determinadas citocinas ou recetores celulares. Entre os DMARDs biológicos aprovados para 
tratamento da AR estão, por exemplo, os anti-TNF (etanercept, infliximab, golimumab, 
adalimumab e certolizumab), o tocilizumab – TCZ (anti-receptor da IL-6) e o rituximab (anti-
CD20). Os DMARDs são conhecidos por melhorarem a capacidade funcional global, 
reduzirem os danos radiológicos e diminuirem os valores clínicos e laboratoriais associados 
à inflamação. Nem sempre os doentes respondem favoravelmente à terapêutica, podendo 
apresentar efeitos secundários graves devido ao efeito imunosupressor e/ ou mantendo 
níveis de atividade de doença elevados, o que obriga muitas vezes a alterações no 
tratamento, procedendo-se a mudanca entre anti-TNFs, ou mesmo para outros biológicos, 
como o TCZ e o rituximab.  
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O principal objetivo deste trabalho consistiu na análise de um grupo de genes relacionados 
com a ativação e sobrevivência dos linfócitos B (BAFF-R, TACI, BCMA), mudança de classe 
e hipermutação somática (AID), diferenciação de plasmócitos (BLIMP-1), quimiotaxia 
(CXCR5), apoptose (BCL- 2), inibição (CD32), inflamação (B2M) e ativação de células B 
através de Toll-like receptors (TLR7, TLR9, TLR10) em doentes não tratados com AR inicial 
(ERA) (≤1 ano de duração da doença) e na comparação da expressão dos mesmos genes 
com doentes com AR estabelecida após tratamento com MTX, MTX pré-biológico (MTX pre-
bio, isto é antes do início de terapêutica com agentes biológicos), anti-TNF e TCZ. Para tal, 
amostras de sangue periférico foram colhidas a doentes ERA (n=13) e AR estabelecidas 
após tratamento com MTX (n=15) e MTX pre-bio (n=25). No grupo de doentes MTX pre-bio, 
foi efetuada uma segunda colheita de sangue a um grupo de doentes com AR após 8 meses 
de tratamento com anti-TNF (n=7) e a outro grupo após 6 meses de tratamento com TCZ 
(n=9). Amostras de sangue de controlos saudáveis (n=15) com a mesma proporção de 
idades e género foram também colhidas e processadas para comparação de resultados. 
Procedeu-se ao isolamento das células mononucleares do sangue periférico (linfócitos B e 
T, monócitos e granulócitos) e, posteriormente, separam-se os linfócitos B. De seguida, a 
partir dos linfócitos B isolados com purezas acima dos 90%, extraiu-se o RNA, sintetizou-se 
o DNA complementar (cDNA) e fizeram-se ensaios de PCR em tempo real para estudar a 
expressão génica do grupo de genes acima mencionados. 
 
Os resultados da expressão génica revelaram um aumento dos níveis de mRNA do BAFF-R 
no grupo de doentes com AR estabelecida tratados com MTX (p=0.0212) e anti-TNF 
(p=0.0025) relativamente aos controlos. Além disso, também se observou um aumento da 
expressão do BAFF-R no grupo de doentes tratados com anti-TNF quando comparado com 
os doentes ERA (p=0.0006). Por outro lado, nao foram observadas diferenças significativas 
na expressão génica de TACI e BCMA em todos os grupos analisados. A análise da 
expressão génica dos Toll-like receptors revelou diferenças significativas nos grupos de 
doentes com AR estabelecida em comparação com os controlos. De facto, verificou-se um 
aumento da expressão de TLR7 e TLR10 no grupo de doentes com AR estabelecida 
tratados com anti-TNF em relação aos controlos (p=0.0385 e p=0.0097, respetivamente) e, 
além disso, foi também observado um aumento da expressão do gene TLR10 nos doentes 
tratados com anti-TNF quando comparados com os doentes ERA (p=0.0801). 
Adicionalmente, foi observado um aumento da expressão do gene TLR9 nos linfócitos B do 
grupo de doentes com AR estabelecida após tratamento com MTX relativamente aos 
controlos (p=0.0043). Verificou-se também uma sobreexpressão do gene B2M em todos os 
grupos de AR estabelecida quando comparados com os controlos: MTX (p=0.0099), MTX 
pre-bio (p=0.0116), anti-TNF (p=0.0025) e TCZ (p=0.0112), embora não tenham sido 
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detetadas diferenças significativas nos doentes ERA. Observou-se ainda que os níveis de 
expressão do gene BCL-2 estavam significativamente elevados em doentes com AR 
estabelecida após tratamento com MTX (p<0.0001), MTX pre-bio (p<0.0001), anti-TNF 
(p=0.0014) e TCZ (p=0.0042) não só em comparação com os controlos, mas também com 
os doentes ERA (p<0.0001). Além disso, verificou-se um aumento significativo nos níveis de 
expressão génica de CD32 nos doentes com AR estabelecida após tratamento com anti-
TNF quando comparados com os controlos (p=0.0043) e com os doentes ERA (p=0.0015). 
Observou-se ainda um ligeiro aumento da expressão génica de CD32 em doentes com AR 
estabelecida após tratamento com MTX pre-bio relativamente aos controlos (p=0.0487). 
Contudo, foi observado um aumento significativo da expressão de CD32 neste grupo 
quando comparado com os doentes ERA (p=0.0015). Adicionalmente, não foram 
observadas diferenças significativas na expressão génica de CXCR5, AID e BLIMP-1 em 
todos os grupos analisados.  
 
Por fim, quando se procedeu à análise da expressão génica antes e após o tratamento com 
anti-TNF e TCZ, não foram observadas quaisquer diferenças significativas para todos os 
genes estudados. Em relação aos dados clínicos dos doentes, verificou-se ainda que o 
tratamento com TCZ comparativamente com as outras terapêuticas estudadas, parece ser o 
mais eficaz a reduzir significativamente os valores séricos da proteina-C reativa, a 
velocidade de sedimentação e a actividade geral da doença indicada pelo DAS28. De 
salientar, no entanto, que nao foi observada nenhuma correlação significativa entre a idade, 
os valores da proteína-C reactiva, a velocidade de sedimentação, o DAS28 e o numero de 
articulações dolorosas e tumefactas com os resultados obtidos da expressão génica para 
todos os grupos estudados, independentemente do tratamento administrado aos doentes.  
 
 
Com a realização deste estudo foi possível concluir que em doentes com AR estabelecida 
existem alterações na expressão de genes associados à ativação dos linfócitos B, quer 
através do recetor do BAFF (BAFF-R), quer através de TLRs (TLR7, TLR9, TLR10); e/ ou à 
inibição de linfocitos B (CD32), assim como perturbações na expressão de genes 
associados à inflamação (B2M) e apoptose (BCL-2). Nos doentes com AR estabelecida, o 
tratamento com anti-TNF e TCZ parece influenciar a expressão destes genes em 
comparação com os indivíduos saudáveis, embora nao sejam detectadas diferenças 
significativas na expressão génica em relação à fase anterior ao início do tratamento. Além 
disso, a expressão génica em doentes não tratados com AR inicial com menos de 1 ano de 
duração da doença parece ser semelhante a dos indivíduos saudáveis. Estes resultados 
sugerem que a expressão génica de linfócitos B em doentes com AR sofre alterações em 
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diferentes fases de desenvolvimento da doença, podendo ser influenciada pelas opções 
terapêuticas.  
 
 
 
 
 
Palavras-chave: Artrite Reumatóide, Linfócitos B, Expressão génica, Metotrexato, Anti-TNF, 
Tocilizumab 
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ABSTRACT 
 
Rheumatoid arthritis (RA) is a systemic autoimmune disease that mainly affects the joints. 
The clinical success of B cell depletion therapy with rituximab in RA has reinforced the role of 
B cells in RA pathogenesis. Indeed, recent studies have shown that very early RA patients 
(with less than 6 weeks of disease duration) have disturbances in circulating memory B cells 
and increased levels of cytokines directly related with B cell activation and survival, which 
supports an active role of B cells in RA development since early disease onset.  
The main goal of the present study was to analyze the expression of a group of genes 
directly related with B cell activation, maturation and survival in untreated early RA (ERA) (< 
1 year of disease duration) and established RA patients after treatment with methotrexate 
(MTX), MTX pre-biologic (MTX pre-bio), TNF inhibitors and tocilizumab (TCZ) in order to 
compare the effects of the therapeutic options on B cell gene expression. For that, blood 
samples were collected from patients and age and sex-matched healthy donors. B cells were 
isolated, RNA extracted, cDNA synthesized and gene expression analysis performed by real 
time PCR. 
 
We found that ERA patients have similar B cell gene expression levels when compared to 
healthy controls. However, increased gene expression was observed in BAFF receptor 
(BAFF-R), Toll-like receptors (TLR7, TLR9, TLR10), inhibition marker (CD32) and in genes 
associated with either active inflammation (B2M) or apoptosis (BCL-2) signaling pathways in 
established RA patients when compared to controls. No significant differences were 
observed in TACI, BCMA, CXCR5, AID and BLIMP-1 gene expression in all groups 
analyzed. Furthermore, the analysis of B cell gene expression levels in established RA 
patients after treatment with TNF inhibitors and TCZ in comparison with baseline values did 
not reveal significant differences. 
 
Overall, these results suggest that the expression of genes related with B cell activation and 
survival are increased in later stages of RA development, which might be influenced by 
treatment options when compared to healthy individuals. Moreover, B cell gene expression in 
early RA patients does not seem to significantly change during the first year of RA 
development when compared to controls. 
 
 
 
Keywords: Rheumatoid arthritis, B cells, Gene expression, Methotrexate, TNF inhibitors, 
Tocilizumab  
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1. RHEUMATOID ARTHRITIS 
 
1.1 Definition 
Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory disease that affects ~0.5%–
1% of the adult population 1. It is characterized by a peripheral polyarthritis that leads to 
deformity through the stretching of tendons and ligaments and destruction of joints through 
the erosion of cartilage and bone. If not 
treated, this autoimmune disease 
causes major disabilities which account 
for socioeconomic burden. Moreover, 
patients with RA have reduced life 
expectancy due to systemic 
manifestations 2,3. Disease onset usually 
occurs between 30-50 years of age and 
is more frequent in women than men 
(ratio 3:1) 4.  
The origin of RA is not associated to a single mechanism but it is known to involve a complex 
dysregulation in the immune system, genotype influence and environmental interactions. 
Thus, RA is presented as a heterogeneous condition mainly characterized by synovial 
inflammation and hyperplasia (swelling), cartilage and bone destruction, and systemic 
features, including cardiovascular, pulmonary, psychological, and skeletal disorders 5,6. 
 
 
1.2 Diagnostic and clinical assessment 
For years, RA diagnosis was established according to the 1987 American College of 
Rheumatology (ACR) criteria (Table 1) 7. In 2010, the ACR and the European League 
Against Rheumatism (EULAR) developed a new criteria that allowed more specificity when 
distinguishing RA from other joint diseases and more sensitivity to identify individuals in the 
early stages of RA (Table 2) 8–10.  
The early stages of RA are mainly characterized by a symmetrical polyarthritis that affects 
the small joints of the hands and feet (metacarpophalangeal, proximal interphalangeal and 
metatarsophalangeal joints) before larger joints are affected 11. Due to synovial hypertrophy, 
the joints become swollen, promoting pain and stiffness. Moreover, the levels of inflammatory 
markers in the blood, such as erythrocyte sedimentation rate (ESR) and C-reactive protein 
(CRP) raise 12,13. Progression of joint damage in patients with RA is also highly correlated 
with overall levels of disease activity assessed by the disease activity score of 28 joints 
Fig. 1 – X-ray from a normal hand (left) and a hand from 
a patient with rheumatoid arthritis (Adapted from WebMD) 
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(DAS28), which comprises the count of 28 tender or swollen joints in the hands, upper limbs 
and knees.14. The joints are also evaluated by imaging studies but these changes frequently 
take several years to develop 15. 
 
Table 1 - The ACR 1987 criteria for classification of 
RA (adapted from 
6
) 
 
 
The presence of autoantibodies such as 
rheumatoid factor (RF) and anti-citrullinated 
protein antibodies (ACPA) (or anti-cyclic 
citrullinated peptides (anti-CCP)) in serum is 
also a characteristic of this autoimmune 
condition, although patients seronegative for 
these antibodies also manifest the disease 16,17.  
 
Table 2 - New classification criteria for rheumatoid arthritis (Adapted from 
6
) RF = rheumatoid factor; ACPA= 
antibodies against citrullinated antigens; CRP= C-reactive protein; ESR = erythrocyte sedimentation rate 
 
RF are autoantibodies that directly bind to the Fc portion of normal human IgG and ACPA 
are autoantibodies that recognize peptides or proteins containing citrulline, a non-standard 
ACR 1987 criteria 
1. Morning stiffness (at least 1h)  
2. Arthritis of three or more joint areas 
3. Arthritis of hand joints (≥1 swollen joints) 
4. Symmetrical arthritis 
5. Rheumatoid nodules  
6. Serum rheumatoid factor 
7. Radiographic changes (erosions) 
Four of these seven criteria must be present. 
Criteria 1–4 must have been present for at 
least 6 weeks 
ACR/ EULAR 2010 criteria 
1. Joint involvement (0–5) 
 One medium-to-large joint (0) 
 Two to ten medium-to-large joints (1) 
 One to three small joints (large joints not counted) (2) 
 Four to ten small joints (large joints not counted) (3) 
 More than ten joints (at least one small joint) (5) 
2. Serology (0–3) 
 Negative RF and negative ACPA (0) 
 Low positive RF or low positive ACPA (2) 
 High positive RV or high positive ACPA (3) 
3. Acute-phase reactants (0–1) 
 Normal CRP and normal ESR (0) 
 Abnormal CRP or abnormal ESR (1) 
4. Duration of symptoms (0–1) 
 Less than 6 weeks (0) 
 6 weeks or more (1) 
Points are shown in parenthesis. Cutpoint for rheumatoid arthritis 6 points or more. Patients can 
also be classified as having rheumatoid arthritis if they have: (a) typical erosions, (b) long-standing 
disease previously satisfying the classification criteria 
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aminoacid generated by the post-translational modification of arginine by peptidylarginine 
deiminase (PAD) enzymes, in a process known as citrullination 18. RF and ACPA can form 
immune complexes that deposit in the joints, activate complement and cause inflammation. 
The clinical usefulness of RF and ACPA has been acknowledged due to their good 
diagnostic sensitivity and prognostic value 17,19. Of note, RF and ACPA can develop several 
years before clinical onset 16.  
 
 
1.3 Etiology and pathophysiology 
The etiology of RA is unknown. However, the development of this autoimmune disease 
seems to be a multistage process in which a number of genetic and environmental factors 
trigger the development of undifferentiated arthritis and a subsequent amount of stimuli are 
required for progression towards joint inflammation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The synovial joint is composed of two adjacent bony ends each covered with a layer of 
cartilage, separated by a joint space and surrounded by the synovial membrane and joint 
capsule. The synovial lining (facing the cartilage and bone) consists of a thin layer of 
synoviocytes (macrophage and fibroblast-derived cells) that constitute the cellular part of the 
synovium. In healthy individuals, the synovium is almost an acellular structure (Fig. 2a) 20. 
Contrarily, in RA, a variety of mononuclear cells such as T cells, B cells, plasma cells, 
dendritic cells, macrophages and mast cells infiltrate the synovial membrane through the 
endothelia, forcing it to expand and become hyperplasic (Fig. 2b) 21. Hyperplasia also results 
(c) 
Fig. 2 - Pathogenesis of RA (Adapted from 
158,159
) a) represents the normal synovium; b) in RA the immune 
cells inflitrate the synovium making it hyperplastic with extensive angiogenisis; c) the adaptive and innate 
immune processes in the joint of RA 
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from a marked increase in macrophage-like and fibroblast-like synoviocytes as they produce 
cytokines and factors that maintain inflammation by activating either themselves or their 
neighboring cells 22.  
RA pathogenesis involves a complex network between cells from both innate and adaptive 
immune system (Figure 2c). An initial trigger activates macrophages in the synovial 
membrane, mediated locally through the action of antigen-activated CD4+ T helper cells 23. 
The T cells invading the synovial membrane are primarily CD4+ memory cells, which produce 
interleukin-2 (IL-2) and interferon-gamma (IFN-γ), and are either already pre-activated or 
become further activated by antigen-presenting cells (APC) in conjunction with arthritogenic 
(auto)antigen(s) and appropriate MHC class-II molecules, co-stimulation (mainly through 
CD80/86 and CD28) and certain cytokines (IL-1, IL-15, IL-18) 24. Activated T cells stimulate 
monocytes, macrophages and synovial fibroblasts. This will lead to an overproduction of pro-
inflammatory cytokines, mainly TNF 25, IL-1 26 and IL-6 27, which seem to constitute a key 
event leading to chronic inflammation 28–30. TNF and IL-1 also induce receptor activator of 
nuclear factor-кB (RANK) expression on macrophages that, after binding to RANK ligand 
(RANKL), stimulates macrophage differentiation into osteoclasts, which consequently resorb 
and destroy bone 31. Chondrocytes also become activated under the influence of IL-1 and IL-
17A, leading to the release of metalloproteinases 5. Moreover, locally expressed degradative 
enzymes, serine proteases and aggrecanases, digest the extracellular matrix and destroy the 
articular structures 20. An extensive angiogenesis process also occurs in RA, promoted by 
vascular endothelium growth factor (VEGF) production by monocytes, endothelial cells and 
synovial fibroblast in response to all the inflammatory stimuli, hypoxia and reduced apoptosis 
32. This supports the formation and maintenance of pannus, a membrane of fibrovascular 
tissue that invades and destroys cartilage and bone 33. 
 
Recent studies also implicate IL-17-producing T cells (TH17) as important effectors in RA 
pathogenesis due to the overexpression of IL-17 in the synovial joints, which is associated 
with an aggravation of inflammation and joint damage 34,35. In fact, a neutrophil- and TH17-
driving cytokine pattern is present in the serum of untreated patients with very early RA 36. 
Regulatory T cells (TRegs) have also been detected in the synovium of RA patients with active 
disease and particularly in synovial fluid, but they seem to have impaired regulatory function 
37. The cytokine factors that sustain the expansion of TRegs in the rheumatoid joint are not 
defined but probably include the regulatory cytokines IL-10 and TGF-β 38.  
B cells also have a relevant role in RA pathogenesis 39, namely through autoantibody 
production (RF, ACPA), antigen presentation and cytokine release upon activation. Indeed, B 
cells produce RF and ACPA that form immune complexes that deposit in the joints. These 
immune complexes activate macrophages through Fc-gamma receptors (FcγR) that release 
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pro-inflammatory cytokines (TNF, IL-1, IL-6) 23 that exacerbate the inflammatory process as 
previously described. Furthermore, it has been recently demonstrated that a cytokine pattern 
directly related with B cell activation and survival is present since the first weeks of RA onset, 
which supports an early intervention of B cells in RA development 40. 
 
 
1.4 Genetic factors and environment 
RA comprises several genetic and environmental associations that are supposedly 
responsible for some alterations in post-transcriptional regulation 5. Twin studies have 
demonstrated a genetic role and showed that genetic factors contribute to 60% of risk of 
developing RA 41. The first established association was related with genes within the HLA 
(human leucocyte antigen) region, particularly the HLA-DRB1 allele that is associated with 
severe rheumatoid arthritis 42–44. This gene encodes major histocompatibility complex (MHC) 
class-II β-chain molecules whose function is the presentation of antigen to CD4+ T cells. 
HLA-DRB1 alleles contain a common aminoacid motif termed “shared epitope” (SE) – a five 
aminoacid sequence motif in residues 70–74 of the HLA-DRβ chain 45. When antigens 
undergo post-translational modifications by citrullination (conversion of the aminoacid 
arginine to citrulline) this change allows antigens to fit in the HLA alleles that harbor this 
shared epitope which might result in breaking of tolerance that allows antibody formation 
against these antigens 46,47. In fact, HLA class II alleles such as DR4 that form the ‘shared 
epitope’ are not primarily a risk factor for RA, but for the presence of ACPA 48. A second 
association was established with the protein tyrosine phosphatase non-receptor 22 
(PTPN22) gene, known to exert a negative feedback effect on the transmission of the signal 
generated by the T cell receptor (TCR) 5,32. These genetic associations might explain the 
emergence of autoreactive responses in antigen presentation, T cell repertoire selection and 
alterations in peptide affinity 6. Other genes linked to RA susceptibility were also associated 
with the NF-кB pathway (REL, TRAF1, and TNFAIP3) 49 and other pathways related to T cell 
activation such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) that suppresses the interaction 
between T cells and antigen-presenting cells (APC); and signal transducer and activator of 
transcription protein 4 (STAT-4), responsible for transducing cytokine signals that regulate 
proliferation, survival and differentiation of lymphocytes 50.  
The environmental risk factors in RA include age and gender 18, a previous family history of 
RA 51, smoking 52–54, obesity 55 , cardiovascular events 56 and some infectious agents 57,58. In 
fact, it has been documented that changes in the female hormonal environment such as 
pregnancy, breastfeeding and the use of the oral contraceptive might affect the development 
of RA 59–61.  
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Some studies have also reported that the formation of immune complexes during exposure 
to some infectious agents might trigger the induction of RF autoantibodies, which have long 
been implicated in RA pathogenesis 58. Nonetheless, the most well-established 
environmental association with RA is smoking. Indeed, cigarette smoking has been 
associated with a consistently increased risk of developing RA, particularly in individuals that 
express the HLA-DRB1 SE alleles 53,54.  
Overall, while RA susceptibility is genetically determined, disease onset may depend on non-
genetic (i.e. environmental), epigenetic or post-translational events. 
 
 
1.5 Treatment 
Although no cure has been found for RA, it is clear that establishing a diagnosis as early as 
possible and immediate treatment are the basis for a successful management of these 
patients 62. The main goals of RA treatment are the preservation of function and quality of 
life, remission of symptoms and control of systemic manifestations. Improvement in RA is 
defined by an outcome measure called ACR 20, ACR 50 or ACR 70, that is characterized as 
a reduction by 20, 50 or 70%, respectively, on the number of tender or swollen joints plus 
improvement in at least three of the five measures: pain, global assessment by the patient 
and levels of acute-phase reactants 6,63. Treatment options are divided in three main classes: 
1) nonsteroidal anti-inflammatory drugs (NSAIDs); 2) corticosteroids; and 3) disease 
modifying anti-rheumatic drugs (DMARDS) (synthetic and biologic) 64. RA patients should 
begin their treatment with DMARDs, which not only relieve symptoms but also slow the 
progression of the disease. Often, DMARDs are prescribed along with NSAIDs and/or low-
dose corticosteroids to decrease swelling and pain 6. DMARDs have greatly improved the 
symptoms, function and quality of life of nearly all patients with RA. Synthetic DMARDs 
include methotrexate, leflunomide, sulfasalazine (SSZ) and hidroxychloroquine (HCQ), which 
are widely used in RA and have proven to be highly beneficial in decreasing inflammation 
and joint damage 64. Gold used to be also administrated to RA patients, but nowadays is 
rarely prescribed since other drugs work better and/ or have fewer side effects 65. 
Nevertheless, patients still fail conventional DMARD therapy, maintaining a high disease 
activity and/ or suffering from severe adverse effects. In these cases, it is recommended that 
biologic DMARD therapy is initiated 64,66. Biologic DMARDs include TNF antagonists 67, which 
are sub-divided in neutralizing anti-TNF monoclonal antibodies (infliximab, adalimumab, 
golimumab, certolizumab) and a soluble TNF receptor-2–IgG-Fc fusion protein (etanercept) 
68. Other biologic therapies include abatacept, a fusion protein composed of the Fc region of 
IgG1 fused to the extracellular domain of cytotoxic T-lymphocyte antigen (CTLA)-4 that binds 
to the CD80/ CD86 molecule and inhibits T cell activation 69, anakinra, an IL-1 receptor (IL-
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1R) antagonist 26; tocilizumab, an IL-6 receptor (IL-6R) blocking monoclonal antibody 70 and 
rituximab, an anti-CD20 B-cell-depleting monoclonal antibody 71.  
 
1.5.1 Methotrexate 
Methotrexate (MTX) is an anti-metabolite and a folate analog designed to compete for folate 
receptors, which affects the de novo synthesis of purine and pyrimidine precursors of DNA 
and RNA 72. MTX also has anti-inflammatory effects at low doses 73. MTX inhibits T-cell 
activation and proliferation, downregulates the expression of some activation and adhesion 
molecules, decreases immunoglobulin production, inhibits cyclooxygenases and 
lipooxygenases, and modulates the secretion of various cytokines by monocytes and 
macrophages. MTX, administrated alone or in combination with either synthetic or biologic 
DMARDs remains the first drug of choice for patients with RA 74. 
 
1.5.2 TNF antagonists 
TNF binds to two receptors, the type 1 TNF receptor (TNFR) (p55) and the type 2 TNFR 
(p75), that is expressed on many cell types, such as monocytes, T cells, B cells, NK cells, 
PMNs, mast cells, synovial fibroblasts and osteoblasts 22. TNF antagonists include 
neutralizing monoclonal antibodies such as infliximab, adalimumab or golimumab and a 
fusion protein, etanercept. Infliximab, is a chimeric IgG1 anti-TNF antibody containing the 
antigen-binding region of a mouse antibody and the constant region of a human antibody. It 
binds with high affinity to soluble and membrane-bound TNF, impairing the binding of TNF to 
its receptor. Infliximab also kills cells that express TNF through antibody-dependent and 
complement-dependent cytotoxicity (ADCC). Adalimumab and golimumab are recombinant 
human IgG1 monoclonal antibodies that bind to human TNF with high affinity, both impairing 
TNF binding to its receptors and lysing cells that express TNF on their surface. Etanercept, a 
soluble TNFR fusion protein composed of two dimers, each with an extracellular, ligand-
binding portion of the higher-affinity type 2 TNFR (p75) linked to the Fc portion of human 
IgG1. This fusion protein binds to both TNF-α and TNF-β, thereby preventing each from 
interacting with its respective receptors. TNF antagonists are more effective when co-
prescribed with MTX. Switching between anti-TNF treatments after secondary treatment 
failure can be associated with a sustained clinical improvement. Although usually effective, 
all anti-TNF treatments are associated with an enhanced risk of infections compared to non-
biological DMARDs 69.  
 
1.5.3 Tocilizumab 
IL-6 forms a complex by binding to IL-6R on the cell membrane, which then combines with 
gp130 that also resides on the cell membrane, forming a homodimer and giving rise to 
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intracellular signal transduction 27. Tocilizumab (TCZ) is a recombinant monoclonal antibody 
that inhibits the induction of biological activity due to IL-6 in cells that express both 
membrane-bound IL-6R and gp130 molecules, and also inhibits the induction of biological 
activity due to IL-6/IL-6R complex formation in cells that express gp130 alone 75. Inhibition of 
IL-6 significantly has showed improved signs and symptoms of RA and normalized the acute-
phase reactants 76.  
 
1.5.4 Rituximab 
CD20 is expressed almost exclusively by B cells at different stages of differentiation, but it is 
not expressed by stem cells or by earlier precursors (i.e. pro-B cells), or by terminally 
differentiated plasma cells 77. Rituximab (RTX) is a monoclonal antibody that selectively 
depletes B cells by directly binding to CD20 78. RTX depletes B cells by inducing cell lysis, 
which can be mediated by complement-dependent cytotoxicity, antibody-dependent cell-
mediated cytotoxicity or apoptosis 79,80. The efficacy of B cell depletion therapy with RTX in 
RA patients has reinforced the relevance of B cells in RA pathogenesis 81–83. Importantly, 
RTX is generally well tolerated, with low risk of infections. 
 
 
 
Fig. 3 - Biologic agents and its targerts (Adapted from 
84
) 
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2. B CELLS 
 
2.1. B cell development 
In adults, B cell development starts in the bone marrow. The B cell progenitor (pro-B cell) is 
the earliest distinctive B-lineage maturation stage, characterized by recombination activating 
gene (RAG)-mediated V, D and J region rearrangement of the immunoglobulin heavy-chain 
locus. Pro-B cells proliferate in the bone marrow and differentiate into precursor B cells (pre-
B cells), characterized by the expression of the cell surface pre–B-cell receptor (BCR).The 
bone marrow stages of human B-cell development are characterized by the expression of 
CD19 by pro-B cells and the subsequent expression of CD20 by pre-B cells, the 
rearrangement of the heavy-chain and light-chain immunoglobulin (Ig) loci, and the 
expression of cell surface IgM. In bone marrow, autoreactive B cells are eliminated through 
apoptosis or undergo immunoglobulin receptor editing 85. Some evidence suggest that these 
tolerogenic mechanisms can be compromised during autoimmune processes 86. Once IgM 
and IgD surface expression are fully achieved, these immature B cells leave the bone 
marrow into circulation as naïve B cells. These naïve B cells, which have never encountered 
an antigen, circulate in the blood and lymphatic systems and are carried to secondary 
lymphoid organs (lymph nodes, spleen, Peyer’s Patches), where they further differentiate. In 
the presence of antigens, naïve B cells are stimulated via T-dependent and independent 
pathways in germinal centers (GC) and in the marginal zones (MZ) of lymphoid organs and 
differentiate into memory B cells or plasma cells 78,85,87. 
 
2.2. B cells and rheumatoid arthritis  
For years, RA was considered a T-cell driven disease 88,89. However, the disappointing 
results obtained with anti-CD4 therapy in humans reinforced the notion that perhaps other 
parts of the inflammatory process of RA should be better studied and understood 90,91. 
B cell activity has become a subject of research not only because of the clinical success of B 
cell depletion therapy with rituximab 81,83, but also because the breakdown of tolerance 
mechanisms that normally regulate B cell development has been associated with 
autoimmunity 92,93. Importantly, recent studies have shown that very early RA patients (with 
less than 6 weeks of disease duration) have disturbances in circulating memory B cells 94 
and increased levels of cytokines related with B cell activation and survival 36,40, which 
supports an active role of B cells in RA pathogenesis since early disease onset. Furthermore, 
histological studies have demonstrated that B cells highly infiltrate the synovial membrane, 
particularly memory B cells and plasma cells 95,96. Of note, the lymphocyte infiltrate in the 
synovium comprises various patterns of structural organization in which B cells are present: 
cells can be diffusely distributed, loosely aggregated or form ordered structures that contain 
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GCs (occurring in <20% of individuals affected with RA). The formation of ectopic GCs may 
contribute to the development of emerging self-reactive B cells as a result of local affinity 
maturation and receptor editing. Indeed, their presence may predispose to poorer outcome 
97.  
B cells can contribute to RA pathogenesis by several mechanisms (see figure 4): 
1) Autoantibody production, such as RF and ACPA, to various synovium-derived antigens 
such as type II collagen, fibrinogen and filaggrin among others.  
2) Antigen presentation and T cell activation. B cells can act as efficient APCs and stimulate 
T cells, allowing the development of memory T-cell subpopulations 98. Furthermore, T cell 
response in RA synovitis and ectopic lymphoid organization is B cell dependent 99. RF+ B 
cells are believed to play an important role in antigen presentation. In fact, it has been 
demonstrated that they can take up antigen–antibody immune complexes through their 
membrane Ig receptors, which have RF specificity 100.  
3) Cytokine and chemokine secretion. B cells sequentially stimulated through the BCR and 
CD40 proliferate and secrete TNF, lymphotoxin-α and IL-6 that amplify the ongoing immune 
response 101.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 - The multiple roles of B cells in RA (Adapted from 
102
) Immune responses potentially orchestrated by B 
cells in rheumatoid arthritis. B-T cell interactions result in the activation and differentiation of plasma cells, 
responsible for the production of autoantibodies (1). In turn, activated B cells provide help to T cells and induce 
differentiation of effector T cells that produce proinflammatory cytokines (2). B cells can also impact on other 
immune and nonimmune cell functions through secretion of cytokines, such as interleukin (IL)-1, IL-6, TNF-α, and 
IL-17A (3). Proinflammatory cytokines and receptor activator of nuclear factor κB ligand (RANKL) produced by 
activated B cells, T cells,macrophages, and synovial fibroblasts promote the differentiation and activation of 
osteoclasts, leading to bone resorption (4). Further participation of B cells in bone homeostasis is suggested by 
the recognition that autoantibodies recognizing citrullinated vimentin are able to promote the differentiation 
ofmononuclear cells to osteoclasts (4). B cells can also be immunoregulatory through the provision of IL-10 and 
other mechanisms yet to be elucidated (5). 
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4) Osteoclast activation. B cell survival and activation signals are manly provided by TNF-
superfamily members. B cells represent also a major source of RANKL in the rheumatoid 
environment, suggesting their direct involvement in the process of osteoclastogenesis and, 
consequently, bone erosion 103. 
5) Immunoregulation. Recent studies indicate the presence of a subset of B cells – B 
regulatory cells (Breg) – specifically induced under inflammatory conditions that are capable of 
suppressing inflammation and/or enhancing the recovery process 104. Breg can act through: a) 
IL-10 production, which restores Th1/Th2 balance and directly inhibits inflammatory 
cascades; b) TGF-β1 production, which induces apoptosis of effector T cells; c) suppression 
of activated CD4+ T cells and d) interaction with other immune cells either directly or through 
secreted antibodies (reviewed in 38).  
 
 
3. AIMS 
 
The main goals of the present study were: 
 
I. To analyze the expression of a group of genes directly related with B cell activation, 
maturation and survival in untreated early RA and established treated RA patients 
 
II. To compare the effects of treatment options (methotrexate - MTX; TNF antagonists 
and Tocilizumab - TCZ) on B cell gene expression in established RA patients  
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4. MATERIALS AND METHODS 
 
Patients  
Blood samples were collected from 13 consecutive patients with untreated polyarthritis 
(Rheumatology Department, Hospital de Santa Maria, Lisbon) of ≤ 1 year disease duration. 
After a minimum follow-up of 3 months, the patients fulfilled the 2010 ACR/ EULAR criteria 
for RA and were classified as early RA (ERA). In addition, blood samples from 15 patients 
with established RA treated with methotrexate (MTX); 25 patients with established RA 
treated with MTX before starting biologic DMARD therapy (MTX pre-biologic, MTX pre-bio); 7 
patients under treatment with TNF inhibitors and 9 patients under tocilizumab (TCZ) 
treatment were also collected for comparison (Rheumatology Department, Hospital de Santa 
Maria, Lisbon). Furthermore, blood samples from 15 healthy donors were also collected and 
processed for comparison. 
This study was approved by the local ethics committee (Comissão de Ética do Hospital de 
Santa Maria), and all patients and healthy donors signed an informed consent form. Patient 
care was conducted in accordance with standard clinic practice, and the study was 
performed in accordance with the Declaration of Helsinki (2008). 
 
 
Isolation of peripheral blood mononuclear cells and B cell separation 
Peripheral blood mononuclear cells (PBMC) were isolated from 60 ml heparinized whole 
blood following density gradient centrifugation with Ficoll (Biowest, France). Cellular counts 
were estimated with 0.4% Trypan Blue (Sigma-Aldrich, USA) in a Neubauer’s chamber. B 
cells were isolated by positive MACS Separation using CD19 Microbeads and LS Columns 
(Miltenyi Biotec GmbH, Germany), according to the manufacturer’s instructions. Purity of 
isolated B cells was analysed by flow cytometry using fluorochrome-conjugated CD20 FITC 
(BD Biosciences, USA) and CD3 APC (eBioscience, USA) antibodies. A total of 20000 cells/ 
sample were acquired with LSR Fortessa (BD Biosciences, USA). The remaining B cells 
were stored at -80ºC in RLT Buffer (Qiagen, Germany) supplemented with RNase inhibitor β-
mercaptoethanol (1:100) until further use.  
 
 
RNA extraction and complementary DNA (cDNA) synthesis 
Total RNA was extracted from B cells using the RNeasy Mini kit (Qiagen, Germany) 
according to the manufacturer’s instructions and treatment with RNase-free DNase Set 
(Qiagen, Germany) was performed to avoid contamination of genomic DNA. RNA 
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concentration and purity were determined with NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, USA). Total RNA was reverse-transcribed into cDNA using 
DyNAmoTM cDNA Synthesis Kit for qRT-PCR (Finnzymes, Finland) with Moloney murine 
leukemia virus (M-MuLV) reverse transcriptase, random hexamers (300 ng/l) and 2X RT 
Buffer, according to the manufacturer’s instructions, performed on Piko Thermal Cycler 
(Finnzymes, Finland). The cDNA samples were stored at -20ºC. 
 
 
Real-time quantitative polymerase chain reaction 
The expression of a group of genes directly related with B cell activation, maturation and 
survival was assessed by real-time quantitative polymerase chain reaction (qPCR)  
performed on Rotor-Gene 6000 (Corbett Life Science, USA) using SensiMix SYBR No-ROX 
Kit (Bioline, United Kingdom). The qPCR program consisted of an initial denaturation step at 
95ºC for 10 min, followed by 40 cycles of 95ºC for 15 s, 60ºC for 15 s, and 72ºC for 15 s. 
Genes and primer sequences analyzed in this study are indicated in Table 3. Primers were 
designed using the National Center for Biotechnology Information (NCBI)/ Primer-BLAST. 
The 18S ribosomal RNA (18S rRNA) was used as endogenous controls in relative 
quantification using the standard curve method. All data were analyzed with Rotor-Gene 
6000 Series Software. 
 
 
Statistical analysis 
Statistical differences were determined with GraphPad Prism (GraphPad, San Diego, USA). 
For populations that did not follow a Gaussian distribution, nonparametric tests were used. 
The Mann-Whitney test was used for comparisons between 2 independent groups. For 
comparisons between 3 or more groups, the Kruskal-Wallis and Dunn’s multiple comparison 
tests were used. The Wilcoxon matched pairs test was used for comparisons between 2 
paired groups. Correlation analysis was performed using Spearman’s test. Differences were 
considered statistically significant for p < 0.05.  
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Table 3 - Primers used in real time PCR assay 
GENE NAME SEQUENCES 
18S rRNA 18S ribosomal RNA 
Fw: 5’-GGA GTA TGG TTG CAA AGC TGA-3’ 
Rv: 5’-ATC TGT CAA TCC TGT CCG TGT-3’ 
BAFF-R BAFF receptor 
Fw: 5’-CTG GTC CTG GTG GGT CTG-3’ 
Rv: 5’-ACC TTG TCC AGG GGC TCT-3’ 
TACI 
Transmembrane 
activator and 
Fw: 5’-AGG CTC AGA AGC AAG TCC AG-3’ 
Rv: 5’-CCA GGA AGC AGC AGA GGA-3’ 
BCMA 
B cell maturation 
antigen 
Fw: 5’-AGG ACG AGT TTA AAA ACA CAG GA-3’ 
Rv: 5’-TCA CAG GTG CAT TCT TCC AC-3’ 
CXCR5 
C-X-C chemokine 
receptor 5 
Fw: 5’-GGA GCC TCT CAA CAT AAG ACA GT-3’ 
Rv: 5’-ATT TTC CAC CAG GGA GGT GTC-3’ 
AID 
Activation-induced 
cytidine deaminase 
Fw: 5’-GGA CTT TGG TTA TCT TCG CAA T-3’ 
Rv: 5’-GTC GGG CAC AGT CGT AGC-3’ 
BLIMP-1 
B lymphocyte-induced 
maturation protein 
Fw: 5’-ACG TGT GGG TAC GAC CTT G-3’ 
Rv: 5’-CTG CCA ATC CCT GAA ACC T-3’ 
β2M β2 – Microglobulin 
Fw: 5’-CTA TCC AGC GTA CGC CAA AGA TTC-3’ 
Rv: 5’-CTT GCT GAA AGA CAA GTC TGA ATG-3’ 
BCL-2 B-cell lymphoma 2 
Fw: 5’-TTG ACA GAG GAT CAT GCT GTA CTT-3’ 
Rv: 5’-ATC TTT ATT TCA TGA GGC ACG TT-3’ 
FCGR2B 
(CD32) 
FcγReceptor II B 
Fw: 5’-GTG CTA TTC CTG GCT CCT GTT-3’ 
Rv:5’-CGT GTG GGT GGG AAT GAG AT-3’ 
TLR7 Toll-like receptor 7 
Fw: 5’-CAC CTC TCA TGC TCT GCT CTC-3’ 
Rv: 5’-TCT AGC CCC AAG GAG TTT GGA-3´’ 
TLR9 Toll-like receptor 9 
Fw: 5’-GGA CCT CGA GTG TGA AGC AT-3’ 
Rv: 5’-TGG AGC TCA CAG GGT AGG AA-3’ 
TLR10 Toll-like receptor 10 
Fw: 5’-TCT GCT GAG AGA GTG CAA GC-3’ 
Rv: 5’-ACA TGT TGG AGC AGT TGG TCA-3’ 
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5. RESULTS 
 
5.1. Clinical characterization of patients 
A group of untreated polyarthritis patients (n=13) with less than 1 year of disease duration 
and classified as early RA (ERA) according to the 2010 ACR/ EULAR criteria after a 
minimum follow-up of 3 months was included in this study. ERA patients had a mean ± 
standard deviation age of 58±14 years old, 85% were female, 69% were RF positive, 62% 
were anti-CCP positive and DAS28 score was 4.1±2.0. A group of established RA patients 
under MTX treatment (n=15) with a mean age of 55±14 years old, 87% female and a DAS28 
of 2.7±1.2 was also included. Furthermore, a group of established RA patients under MTX 
treatment pre-biological therapy (MTX pre-bio, n=25) with a mean age of 58±12 years old, 
88% female and a DAS28 of 5.2±1.5 was also analyzed. From the MTX pre-bio group, a 
second blood collection was performed to RA patients that had either initiated treatment with 
TNF-inhibitors (n=7) or with tocilizumab (TCZ) (n=9), after an average follow-up of 8 and 6 
months of treatment, respectively. In addition, blood samples were collected from age and 
sex-matched healthy donors (n=15). The clinical information and data from all patients and 
healthy controls included in this study is indicated in Table 4. 
Table 4 - Clinical information of controls, ERA and established RA patients after treatment with MTX, MTX 
pre-bio, TNF inhibitors and TCZ. ERA - Early Rheumatoid Arthritis; RA - Rheumatoid Arthritis; MTX – 
Methotrexate; MTX pre-bio – Methotrexate pre-biologic; TNF – TNF inhibitors; TCZ – Tocilizumab; CRP - C-
reactive protein; ESR - Erythrocyte Sedimentation Rate; VAS – Visual Analogue Scale; DAS28 – Disease Activity 
Score of 28 joints; RF – Rheumatoid Factor; ACPA– anti-cyclic citrullinated peptide; NA – not applicable; ND – not 
determined.  Values are represented as mean ± standard deviation.( ** p < 0.05 in comparison with ERA; # p < 
0.05 in comparison with MTX pre-bio; & p < 0.05 in comparison with TNF) 
 
 
Controls 
(n=15) 
ERA 
(n=13) 
MTX 
(n=15) 
MTX pre-bio 
(n=25) 
TNF 
(n=7) 
TCZ 
(n=9) 
Age (years) 50±7 58±14 55±14 58±12 52±16 61±13 
Sex (% female) 73 85 87 88 80 100 
Disease duration 
(years) 
NA ≤ 1 7±6 11±8 6±3 12±7 
CRP (mg/dl) ND 1.5±2.1 0.5±0.6 1.4±3.1 1.2±1.1 0.2±0.3# 
ESR (mm/1
st
 
hour) 
ND 42±25 23±23 29±16 44±47 4±2**#& 
VAS NA 40±33 42±33 69±18 66±27 67±10 
DAS28 NA 4.1±2.0 2.7±1.2# 5.2±1.5 4.4±1.3 2.9±1.0# 
Swollen joints NA 3±5 1±2# 6±6 3±3 1±1 
Tender joints NA 5±5 2±3# 12±8 7±4 2±3# 
RF (+) % ND 69 87 75 60 86 
ACPA (+) % ND 62 60 78 40 86 
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5.2. Established RA, but not early RA patients have alterations in B cell gene 
expression levels in comparison with healthy controls 
 
In this study, a group of genes related with B cell homeostasis and survival (BAFF-R, TACI, 
BCMA), class-switching (AID), chemotaxis (CXCR5), plasma cell differentiation (BLIMP-1), 
immune system activation (B2M), apoptosis (BCL-2), B cell inhibition (CD32) and activation 
through Toll-like receptors (TLR7, TLR9, TLR10) were analyzed in untreated ERA and 
established RA patients under treatment with MTX, MTX pre-bio, TNF inhibitors and TCZ. 
Results were compared with age and sex-matched healthy controls.  
 
Since some of the studied genes are also expressed by monocytes and T cells, isolating B 
cells from PBMC samples was mandatory. Therefore, the purity of B cell isolation was tested 
for each sample by flow cytometry and samples were excluded if the purity was under 90%. 
Additionally, samples were also excluded if the RNA concentration obtained from isolated B 
cells was too low to perform a gene expression analysis of all genes of interest. 
 
It was found that untreated ERA patients (≤ 1 year of disease duration) have similar B cell 
gene expression levels with no statistically significant differences when compared to healthy 
controls for all genes analyzed (Figures 5-8). However, established RA patients had 
alterations in B cell gene expression levels in comparison with controls. 
 
The analysis of all BAFF receptors has revealed that BAFF-R gene expression was 
significantly increased in established RA patients after treatment with MTX (p=0.0212) and 
TNF inhibitors (p=0.0025) in comparison with the control group (Figure 5). Furthermore, 
BAFF-R gene expression was also significantly increased in established RA patients after 
treatment with TNF inhibitors when compared to ERA (p=0.0006). Nevertheless, no 
statistically significant differences were detected in TACI and BCMA gene expression levels 
in all groups studied. 
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Fig. 5 - BAFF-R gene expression is significantly increased in B cells from established RA patients after 
treatment with MTX and TNF inhibitors. A nonparametric statistical analysis was performed with Kruskall-Wallis 
and Mann-Whitney tests: bars represent median relative gene expression values.  * p < 0.05 in comparison with 
Controls; # p < 0.05 in comparison with ERA. 
 
 
Alterations in the B cell gene expression levels of TLR7, TLR9 and TLR10 were also 
observed in established RA patients (Figure 6). Indeed, it was found that TLR7 and TLR10 
gene expressions were significantly increased in established RA patients after treatment with 
TNF inhibitors when compared to controls (p=0.0385 and p=0.0097, respectively). 
Furthermore, TLR10 gene expression levels were also significantly increased in established 
RA under anti-TNF therapy when compared to ERA patients (p=0.0801). Moreover, TLR9 
gene expression was significantly increased in established RA patients under MTX treatment 
(p=0.0043) when compared to controls. No other statistically significant differences were 
detected in all groups analyzed.  
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Fig. 6 - Established RA patients have alterations in the gene expression levels of TLR7, TLR9 and TLR10 
after treatment with MTX and/ or TNF inhibitors. A nonparametric statistical analysis was performed with 
Kruskall-Wallis and Mann-Whitney tests: bars represent median relative gene expression values.  * p < 0.05 in 
comparison with Controls; # p < 0.05 in comparison with ERA. 
 
The analysis of the gene expression levels of B2M, an inflammatory marker, and CD32 
(FCGR2B), an inhibitory B cell marker, also revealed disturbances in established RA patients 
(Figure 7). It was observed that B2M gene was overexpressed in B cells from established RA 
patients treated with MTX (p=0.0099), MTX pre-bio (p=0.0116), TNF inhibitors (p=0.0025) 
and TCZ (p=0.0112) when compared to controls, but no significant differences were detected 
in ERA patients in comparison with controls. The gene expression levels of CD32 were 
significantly elevated in established RA patients treated with TNF inhibitors in comparison not 
only with controls (p=0.0043), but also with ERA patients (p=0.0015). Furthermore, a 
tendency for increased CD32 gene expression levels was also observed in established RA 
patients treated with MTX pre-bio when compared to controls (p=0.0487). Nonetheless, 
 19 
CD32 gene expression was significantly increased in established RA patients treated with 
MTX pre-bio when compared to ERA patients (p=0.0015). 
 
 
Fig. 7 - Established RA patients have increased gene expression levels of B2M, CD32 and BCL-2 
irrespective of the treatment. A nonparametric statistical analysis was performed with Kruskall-Wallis and 
Mann-Whitney tests: bars represent median relative gene expression values.  * p < 0.05 in comparison with 
Controls; # p < 0.05 in comparison with ERA. 
 
 
In addition, BCL-2 gene was overexpressed in B cells from established RA patients treated 
with MTX (p<0.0001), MTX pre-bio (p<0.0001), TNF inhibitors (p=0.0014) and TCZ 
(p=0.0042) in comparison with controls and also with ERA patients (p<0.0001) (Figure 7).  
 
It was also observed that ERA and established RA patients (irrespective of treatment) had 
similar AID, BLIMP-1 and CXCR5 gene expression levels when compared to healthy controls 
and no significant differences were detected (Figure 8).  
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Fig. 8 - ERA and established RA patients have normal gene expression levels of AID, BLIMP-1 and 
CXCR5. No significant differences were observed in B cell gene expression levels of AID, BLIMP-1 and CXCR5 in 
all groups of patients when compared to healthy controls. 
 
 
 
 
5.3. Treatment with TNF inhibitors and tocilizumab does not affect B cell gene 
expression 
 
In order to understand the effect of treatment options before and after RA patients initiate 
treatment, a second blood collection was performed in established RA patients from MTX 
pre-bio group after a mean period of 8 months of treatment with TNF inhibitors (n=5) or after 
a mean of 6 months of treatment with TCZ (n=7). B cell gene expression levels were 
analyzed after treatment and compared to baseline values. Nevertheless, no statistically 
significant differences were observed in the gene expression levels of all genes studied in 
established RA patients after treatment with TNF inhibitors (Figure 9) or TCZ (Figure 10). 
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Fig. 9 - B cell gene expression is not affected by TNF inhibitors in established RA when compared to 
baseline. B cell gene expression levels of BAFF-R, TACI, BCMA, CXCR5, AID, BLIMP-1, B2M, BCL-2, CD32, 
TLR7, TLR9 and TLR10 were analyzed in established RA patients after 8 months of treatment with TNF inhibitors 
(n=5) and compared to baseline levels. No significant differences were observed in all B cell gene expression 
levels before and after anti-TNF therapy. 
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Fig. 10 - B cell gene expression is not affected by tocilizumab in established RA when compared to 
baseline. B cell gene expression levels of BAFF-R, TACI, BCMA, CXCR5, AID, BLIMP-1, B2M, BCL-2, CD32, 
TLR7, TLR9 and TLR10 were analyzed in established RA patients after 6 months of treatment with TCZ (n=7) and 
compared to baseline levels. No significant differences were observed in all B cell gene expression levels before 
and after treatment with TCZ. 
 
 
3.4. Correlation analysis between B cell gene expression and clinical data 
 
A correlation analysis was also performed between all the B cell gene expression levels of all 
groups included in this study with the clinical parameters previously indicated in Table 3. 
Nevertheless, no correlation was found between B cell gene expression with age, CRP, 
ESR, VAS, DAS28, swollen joints and tender joints in all patients’ groups (data not shown). 
Furthermore, no correlation could be detected between B cell gene expression levels and 
age in the control group (data not shown).  
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6. DISCUSSION 
 
In the present study, a group of genes directly related with B cell activation and survival 
(BAFF-R, TACI, BCMA), class-switching and somatic hypermutation (AID), plasma cell 
differentiation (BLIMP-1), chemotaxis (CXCR5), apoptosis (BCL-2), inhibition (CD32), 
inflammation (B2M) and B cell activation through TLRs (TLR7, TLR9, TLR10) was analyzed 
on peripheral blood isolated B cells from untreated early RA patients (ERA) (≤1 year of 
disease duration) and compared to established RA patients treated with MTX, MTX pre-
biologic therapy, TNF inhibitors and TCZ for a better understanding about the effect of 
treatment options.  
 
Our data has shown that B cell gene expression levels were surprisingly similar in ERA 
patients and healthy controls and, therefore no significant changes in B cell gene expression 
were detected during the first year of RA development. Previous studies by our group have 
found differences in B cell gene expression levels in patients with very early RA – VERA (< 6 
weeks of disease duration) and ERA patients when compared to healthy controls, namely 
increased BAFF and TACI gene expressions 105. Nevertheless, this study was performed on 
PBMC and not on isolated B cells like the present work. Thus, we cannot exclude the 
possibility that different B cell proportions present in PBMC and purified B cell samples might 
affect the results obtained. Moreover, the number of patients included and patient variability 
can also influence the results observed.  
 
Contrarily to ERA patients, significant alterations in B cell gene expression could be 
observed in established RA patients in comparison with controls, depending on the 
treatment. Indeed, disturbances in the gene expression levels were found in BAFF receptors 
(BAFF-R), TLRs (TLR7, TLR9, TLR10), inhibitory markers (CD32) and in genes associated 
with either active inflammation (B2M) or apoptosis (BCL-2) signaling pathways. 
 
B cells can be activated in the context of T-dependent responses, which largely takes place 
in the germinal center and are associated with Ag stimulation through the BCR in the context 
of T cell–derived co-stimulatory signals, such as IL-21 and CD40L 106. Alternatively, B cells 
can be activated by T-independent antigens: for example, by signals delivered through TLRs 
and chronic activation of self-reactive B cells may be initiated through several pathways 107. 
In this regard, BAFF may substitute T cells in B cell activation 108. The receptors for this 
cytokine include BAFF-R, TACI and BCMA, all of which belong to the TNF family. BAFF-R is 
uniformly expressed in the majority of B cell lineage 109 and it has been associated with 
autoimmune diseases such as systemic lupus erythematosus (SLE) 110 and 
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lymphoproliferative disorders 111–113. Of note, an overexpression of BAFF-R has also been 
found in RA synovial tissue and circulating PBMC 105. TACI is mainly expressed on memory 
B cells, plasma cells as well as on a subpopulation of activated CD27neg B cells 109,114; it also 
plays a role in class-switch recombination 115. BCMA expression is induced as a result of 
memory B cell differentiation into Ig-secreting plasma cells and its expression also occurs in 
fibroblast-like synoviocytes through the stimulation of APRIL (a proliferation-inducing ligand) 
116 a cytokine that has affinity to BCMA and TACI receptors and is also implicated in B cell 
development 117. 
 
From all BAFF receptors, BAFF-R was the only significantly increased in established RA 
patients treated with MTX and TNF inhibitors as compared to controls. Previous works have 
found increased BAFF-R gene expression levels in established RA treated with MTX or after 
anti-TNF therapy 105, which further supports our results. Indeed, a study in type II collagen 
(CII)-induced arthritis (CIA) mice found that treatment with etanercept (a TNF inhibitor) was 
associated with an increase in BAFF-R expression and a negative correlation was found 
between the levels of BAFF-R and the percentage of memory B cells 118. Since established 
RA patients treated with TCZ had similar BAFF-R gene expression levels in comparison with 
controls, it seems that TCZ restores BAFF-R to normal gene expression levels. Of note, TCZ 
treatment was the most effective therapy in reducing disease activity (DAS28 score), which 
might justify the results obtained. The normal TACI gene expression observed in all patients’ 
groups, irrespective of the treatment, might reflect B cell signaling mechanisms through other 
receptors. Furthermore, the absence of significant differences in BCMA gene expression are 
probably related to the low number of plasma cells in circulation, which are the main B cell 
subpopulation that express this cell marker. 
 
Disturbances in gene expression levels of TLRs (TLR7, TLR9 and TLR10) were also 
detected in established RA patients. TLRs have been known to play central roles in infection 
and in driving inflammation in RA 107,119,120. Furthermore, TLR signals per se are co-
stimulatory and critically regulate T-independent autoreactive B cell activation and isotype-
switch of Ig genes outside germinal centres 121. From the 10 human TLR subtypes, TLR1, 2, 
4, 5 and 6 have extracellular expression to detect pathogenic elements in the surface, 
whereas TLR3 and TLR7-9 are found primarily in the intracellular endosome and detect 
internalized ligands. TLR7 binds to viral nucleic acids, whereas TLR9 recognizes unmetilated 
C-phosphate-G (CpG) bacterial DNA (reviewed in 122). TLR10 function is still unknown but it 
has been speculated that it might cooperate with TLR2 in detecting lipoproteins 123,124. TLR7 
and TLR9 are mainly expressed in plasmacytoid dendritic cells and B cells, whereas TLR10 
is highly expressed in B cells 125. Previous studies have found that TLR7 and TLR9 mRNA 
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levels are up-regulated in PMBC of primary Sjögren's syndrome patients 126. Of note, TLR7 
has increased expression in RA synovium 127. Moreover, TLR9 gene polymorphisms have 
been indicated as a possible susceptibility factor in RA 128 and it has been suggested that 
TLR9 participates in the activation and proliferation of bone marrow B cells from RA patients 
129. Infection has long been speculated to be an underlying factor in RA pathogenesis, 
although it is still a controversial subject. The presence of peptidoglycan, bacterial and viral 
DNA has been shown in RA joints in previous studies, implicating TLRs’ activation as a 
potential driver of the disease 130. It is possible that B cell activation through BCR signalling 
pathway is inhibited with MTX and TNF inhibitors treatments and, consequently, B cells 
would readjust the expression levels of other activating receptors such as BAFF receptors or 
TLRs, which could justify the results obtained. Nevertheless, studies with a higher number of 
patients and also at the protein level would ideally clarify these results. 
 
CD32 gene expression was also significantly increased in established RA patients after 
treatment with TNF inhibitors in comparison not only with controls, but also with ERA 
patients. Moreover, established RA patients treated with MTX pre-bio also had significantly 
increased CD32 gene expression levels when compared to ERA, although no significant 
differences were detected in comparison with controls. CD32 (FcγRII) is a transmembrane 
glycoprotein that mediates several functions including phagocytosis, cytotoxicity, 
immunomodulation and platelet aggregation 131,132. CD32 is encoded by three genes (A, B, 
C) and different isoforms are generated via alternative mRNA splicing. Only B cells and 
plasma cells express the isoform IIb (FcγRIIB) 133, which has been associated with SLE and 
RA. Indeed, genetic polymorphisms in FcγRIIB have been associated with SLE severity 134,135 
and also with increased radiologic joint damage in RA 136,137. It has been demonstrated that 
CD32 (FcγRIIB) triggering on B cells downregulates antibody production and may, in some 
circumstances, promote apoptosis 131. Furthermore, studies in mice models of arthritis have 
shown that FcγRII reduces joint inflammation by promoting endocytosis and clearance of 
immune complexes from the joint 137. Therefore, it is possible that treatment of established 
RA patients with TNF inhibitors, but not MTX or TCZ, induces an increase in CD32 (FcγRIIb) 
expression that can inhibit B cell activation and disease progression.  
 
β2-microglobulin (B2M) is required for the expression of cell surface molecules, including 
classical major histocompatibility complex (MHC) class I, CD1, Qa-1, and FcRn (neonatal Fc 
receptor), and for the development of CD8+, NKT, and CD3+ CD4- CD8- T cell subsets 138,139, 
all of which may potentially impact the development of humoral autoimmunity. In this study, 
all groups of established RA displayed high levels of B2M gene expression, irrespective of 
treatment. This supports the existence of an inflammatory process associated with B cell 
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activation in RA patients, which is not abrogated by treatment with immunosuppressive 
DMARDs, either synthetic or biologic. 
 
BCL-2 gene, which codes for an important anti-apoptotic protein 140–142, had increased 
expression levels in all established RA groups, irrespective of treatment not only in 
comparison with controls, but also with ERA patients. BCL-2 transgenic expression in the B 
lineage results in B cell hyperplasia without an induction of cell cycle progression in vivo, and 
enhanced survival of peripheral B cells in vitro 143–145. An increased expression of BCL-2 has 
been previously demonstrated in SLE patients and studies with transgenic animals indicate 
that dysregulation of BCL-2 may lead to autoimmune disease resembling human SLE 145. RA 
is associated with an accumulation of inflammatory cells in the joints and their subsequent 
activation and proliferation, suggesting that pro-survival factors such as BCL-2 keep the 
peripheral B cell lifespan, thus contributing to disease persistence and progression. This 
effect does not seem to be abrogated by treatment options.  
 
In addition, no significant differences were found in relative CXCR5, AID and BLIMP-1 gene 
expression in B cells. CXCR5 is a chemokine receptor expressed in recirculating B cells, in 
subsets of CD4+ and CD8+ T cells and monocytes 146. Together with its ligand CXCL13 147, 
mediates migration of B cells into the follicles of the splenic white pulp, thus permitting 
antigen deposition on follicular dendritic cells 148,149. It has been demonstrated that RA 
patients display upregulated expression of CXCR5 to a greater extent than other chemokine 
receptors, and CXCR5-null mice subjected to antigen-induced arthritis display reduced joint 
destruction 150,151 . Although we did not find significant differences in CXCR5 gene expression 
in all groups, we cannot exclude the hypothesis that the expression of this chemokine 
receptor might have been affected at the protein level. AID, a member of the cytidine 
deaminase family, is involved in somatic hypermutation and class-switch recombination of 
immunoglobulin genes, which take place in the GC. Indeed, the molecular mechanism of 
cytosine deamination induces immunoglobulin affinity maturation and antibody class 
switching 152. It has been demonstrated that AID transcripts are increased in rheumatoid 
synovitis 153. Thus, although there were no significant differences in AID gene expression 
levels in circulating B cells, it is possible that locally in the joints higher levels of AID gene 
expression can be found. BLIMP-1 is a transcription factor and regulates the terminal 
differentiation of many types of cells 154, including the differentiation of B cells into plasma 
cells 155. Most plasma cells formed after a T cell–dependent GC reaction secrete antibodies 
with higher affinity and switched isotypes and infiltrate the synovial membrane 156,157. The 
reduced number of circulating plasma cells (usually less than 2-3 %) 94 might justify the 
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results observed. Similarly to AID, BLIMP-1 gene expression levels are probably increased in 
rheumatoid synovium, which is highly infiltrated by antibody-secreting cells. 
 
Overall, disturbances in B cell gene expression levels directly related to B cell activation 
(BAFF-R, TLR7, TLR9 and TLR10) and/ or inhibition (CD32), inflammation (B2M) and 
apoptosis (BCL-2) are present in later stages of RA development. At earlier stages of RA, 
patient variability and disease activity might also affect B cell gene expression levels. 
Furthermore, the effect of treatment is more evident when results are compared to healthy 
individuals and not with baseline values. Nevertheless, larger cohorts of patients and/ or 
analysis at the protein level would be required to allow more robust conclusions that 
enlighten the pathways involved in RA.  
 
 
 
7. LIMITATIONS AND FUTURE PERSPECTIVES  
 
Despite the efforts, it is still important to keep introducing new treatments for RA to overcome 
problems associated with the various factors triggering the disease. Treatments for RA have 
been advancing rapidly and new ones are now on clinical trials 78. The drugs discussed in 
this study appear to be relatively safe and effective in short-to-intermediate term and 
although the effects seem promising, searching for new biomarkers could be very useful to 
achieve a better treatment efficacy. Moreover, it would also be important to study the effects 
of treatment options individually in particular all TNF inhibitors available (infliximab, 
adalimumab, certolizumab, golimumab and etarnecept), since it is possible that different 
drugs can have different effects. Of note, it would also be interesting to study other 
therapeutic approaches such as the B cell depleting drug rituximab and/ or abatacept, a 
fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the 
extracellular domain of CTLA-4 that inhibits T cell activation.  
 
In addition, it would also be important to study individual B cell subpopulations not only at the 
gene level, but also at the protein level to better understand the relevance of all B cell 
subsets in RA development and progression. Nevertheless, the collection of larger patient 
cohorts, which can be a challenging issue in biomedical investigation, would be necessary in 
order to have a more robust and conclusive analysis. 
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